Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LY3839840
- Development stage
- Phase 1
- Lead developer
- Eli Lilly
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
LY3839840 is an investigational small molecule drug developed as an itaconate mimetic. It is being evaluated for its potential in treating immune system and autoimmune diseases. The drug is currently in Phase 1 clinical trials, with studies focused on assessing its safety, tolerability, and pharmacokinetics following oral administration in healthy participants. The precise mechanism of action has not been publicly disclosed but is described as a novel approach within the field of immunomodulation[2][4]. The development was initiated by Sitryx Therapeutics and later licensed to Eli Lilly.
- Other names
- Itaconate mimetic
Beyond the preview
Go deeper on LY3839840.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LY3839840.